Solifenacin objectively decreases urinary sensation in women with overactive bladder syndrome

International Urology and Nephrology

Volumn 44, Issue 2, 2012, Pages 425-429

  Lowenstein, Lior ^a   Kenton, Kimberly ^b   Mueller, Elizabeth R ^b   Brubaker, Linda ^b   Sabo, Edmond ^a   Durazo Arivzu, Ramón A ^b   FitzGerald, Mary P ^b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antimuscarinic; Urgency; Urgeometer; Validity

Indexed keywords

PLACEBO; SOLIFENACIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLADDER CAPACITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOMETRY; DRUG MECHANISM; FEMALE; HUMAN; MEDICAL DEVICE; OVERACTIVE BLADDER; TEST RETEST RELIABILITY; TREATMENT DURATION; TREATMENT RESPONSE; URETHRA PRESSURE; URETHRAL CATHETER; URINARY SENSATION; URINARY TRACT FUNCTION; URODYNAMICS; UROGENITAL SYSTEM PARAMETERS;

AGED; DIAGNOSTIC TECHNIQUES, UROLOGICAL; EQUIPMENT DESIGN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PREDICTIVE VALUE OF TESTS; QUINUCLIDINES; REPRODUCIBILITY OF RESULTS; SENSATION; SYNDROME; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 84863088920     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-011-0059-y     Document Type: Article

References (13)

1. Haylen BT, de Ridder D, Freeman RM et al (2010) An International urogynecological association (IUGA)/ International continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct 21:5-26
2. Oliver S, Fowler C, Mundy A, Craggs M (2003) Measuring the sensations of urge and bladder filling during cystometry in urge incontinence and the effects of neuromodulation. Neurourol Urodyn 22:7-16
3. Lowenstein L, FitzGerald MP, Kenton K, Brubaker L, Gruenwald I, Papier I, Durazo-Arvizu RA, Elliot C, Mueller ER, Vardi Y (2008) Validation of a real-time urodynamic measure of urinary sensation. Am J Obstet Gynecol 198(6): 661.e1-4; discussion 661.e4-5
4. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA (1995) Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Continence program for women research group. Neurourol Urodyn 14:131-139
5. Herzog AR, Diokno AC, Brown MB, Normolle DP, Brock BM (1990) Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults. J Gerontol 45:M67-M74 (Pubitemid 20104848)
6. Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 43:1-5 (Pubitemid 36134308)
7. Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distributionand function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565-578 (Pubitemid 43993048)
8. De Laet K, De Wachter S, Wyndaele JJ (2006) Systemic oxybutynin decreases afferent activityof the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 25:156-161
9. De Wachter S, De Laet K, Wyndaele JJ (2006) Does the cystometric filling rate affect the afferent bladder response pattern? A study on single fibre pelvic nerve afferents in the rat urinary bladder. Neurourol Urodyn 25:162-167
10. Kenton K, Lowenstein L, Simmons J, Brubaker L (2007) Aging and overactive bladder may be associated with loss of urethral sensation in women. Neurourol Urodyn 26:981-984 (Pubitemid 350085897)
11. Andersson KE, Chapple CR (2001) Oxybutynin and the overactive bladder. World J Urol 19:319-323 12. Santos JC, Telo ER (2010) Solifenacin: scientific evidence in the treatment of overactive bladder. Arch Esp Urol 63: 197-213 (Pubitemid 33777077)
12. Santos JC, Telo ER (2010) Solifenacin: scientific evidence in the treatment of overactive bladder. Arch Esp Urol 63: 197-213
13. Vardy MD, Mitcheson HD, Samuels TA et al (2009) Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT-a double-blind, placebo-controlled trial. Int J Clin Pract 63:1702-1714